Karin Rosén moves on from GSK, now play­ing dual roles at Hori­zon; Gilead looks to Jared Baeten to take com­mand of HIV strat­e­gy

→ GSK and Genen­tech alum Karin Rosén is ex­pand­ing her hori­zons, so to speak, tak­ing on the roles of CSO and EVP, R&D at Hori­zon Ther­a­peu­tics. Rosén de­parts for Hori­zon from her gig at GSK as SVP of US med­ical af­fairs, and she was a med­ical af­fairs ex­ec at Aim­mune be­fore then for a short time. At Genen­tech, where she spent 10 years, she was pro­mot­ed to ther­a­peu­tic area head, im­munol­o­gy and worked on sev­er­al Phase II/III pro­grams in im­munol­o­gy, res­pi­ra­to­ry, al­ler­gy and der­ma­tol­ogy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER